Home › Trials › NCT03785249

Treatment for advanced cancer with a KRAS G12C mutation

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Phase1; Phase2 Interventional Mirati Therapeutics Inc. · NCT03785249

This study is testing a new drug called MRTX849 to see if it can help people with advanced cancer that has a specific KRAS G12C mutation feel better and live longer.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment822 (estimated)
Ages18 Years and up
SexAll
SponsorMirati Therapeutics Inc. Industry-sponsored
Locations228 sites (Birmingham, Alabama and 227 other locations)
Trial IDNCT03785249 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of MRTX849 (adagrasib), a small molecule inhibitor, in patients with advanced solid tumors harboring a KRAS G12C mutation. It focuses on assessing drug tolerability, pharmacokinetics, and clinical activity in this specific patient population. Participants will receive MRTX849, with potential combinations including Pembrolizumab, Cetuximab, and Afatinib, depending on their specific cancer type and treatment history.

Who should consider this trial

Good fit: Ideal candidates include patients with unresectable or metastatic solid tumors confirmed to have a KRAS G12C mutation.

Not a fit: Patients with other active cancers or those unable to take oral medications may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a targeted therapy option for patients with KRAS G12C mutated cancers, potentially improving outcomes.

How similar studies have performed: Previous studies targeting KRAS mutations have shown promise, indicating potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
* Unresectable or metastatic disease
* Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
* Adequate organ function

Exclusion Criteria:

* History of intestinal disease or major gastric surgery or inability to swallow oral medications
* Other active cancer

Where this trial is running

Birmingham, Alabama and 227 other locations

+178 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Advanced CancerMetastatic CancerMalignant Neoplastic DiseaseKRASNSCLCColorectal CancerColon CancerPancreatic Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.